Emyria Ltd has released a press release.
Emyria expands clinical sites for EMD-RX5 Phase 3 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Emyria commences US preclinical program for MDMA library
- Appendix 4E and Annual Report
- Positive results received for Emyrias MDMA-inspired program
- Emyria receives ethics approval for EMD-RX5 Phase 3 trial
- Preclinical studies initiated for MDMA-inspired analogues
Later from Emyria
- Emyria and UWA expand unique MDMA-inspired analogue library
- Emyria completes $3m placement
- Placement completion and secondary trading notice
- Emyria accepted into National Institutes of Health Program
- Emyria receives $2.1M R&D tax incentive refund
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria